atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions.[1][2][3][4][5] It was founded in 2018 and is headquartered in Berlin, Germany.[1][5]
The company's pharmaceutical candidates include dimethyltryptamine
In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange.[1][7] In January 2023, atai Life Science's leading drug candidate at the time, arketamine (PCN-101), failed to meet its primary endpoint in a clinical trial.[1] Following that, the company laid off 30% of its staff.[1]
Peter Thiel is a major investor in the company.[1] atai Life Sciences has a 22.4% stake in Compass Pathways.[1][5]
